Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report

Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report

Source: 
Fierce Pharma
snippet: 

In the 1980s, only 4% of new drugs approved by the FDA were cancer treatments. But since 2010, cancer drugs have claimed 27% of new approvals—a share that doubled over the previous decade—according to a new report from the Tufts Center for the Study of Drug Development.